Human CD30 Ligand / TNFSF8 Protein, His Tag, low endotoxin (MALS verified)

Customer Reviews
Cat. No. / Size
Price
Availability
Qty
CDL-H524b-100ug
$395.00
In Stock - Delivery in 2-3 business days
CDL-H524b-1mg (100ug X 10)
$2615.00
In Stock - Delivery in 2-3 business days

Product Details

  • Synonyms

    CD30-L, CD153, TNFSF8, CD30L, CD30LG, CD153 antigen, CD30 antigen ligand, CD30 Ligand

  • Source

    Human CD30 Ligand Protein, His Tag (CDL-H524b) is expressed from human 293 cells (HEK293). It contains AA Gln 63 - Asp 234 (Accession # P32971-1).

    Predicted N-terminus: His

    Request for sequence
  • Molecular Characterization

    CD30 ligand Structure

    Other Tags and Version Biotin & Other Labeled Version

    This protein carries a polyhistidine tag at the N-terminus.

    The protein has a calculated MW of 21.5 kDa. The protein migrates as 30-40 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Endotoxin

    Less than 0.01 EU per μg by the LAL method / rFC method.

  • Purity

    >90% as determined by SDS-PAGE.

    >95% as determined by SEC-MALS.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Shipping and Storage

    This product is shipped at ambient temperature.

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Customers Also Viewed

Performance Data

  • SDS-PAGE

    CD30 ligand SDS-PAGE

    Human CD30 Ligand Protein, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.

  • SEC-MALS

    CD30 ligand SEC-MALS

    The purity of Human CD30 Ligand Protein, His Tag (Cat. No. CDL-H524b) is more than 95% and the molecular weight of this protein is around 60-83 kDa verified by SEC-MALS.

    Report
  • Bioactivity-ELISA

     CD30 ligand ELISA

    Immobilized Human CD30 Protein, Fc Tag (Cat. No. CD0-H5250) at 2 μg/mL (100 μL/well) can bind Human CD30 Ligand Protein, His Tag (Cat. No. CDL-H524b) with a linear range of 0.039-0.313 μg/mL (QC tested).

    Protocol
  •  CD30 ligand ELISA

    Immobilized Human CD30 Ligand Protein, His Tag (Cat. No. CDL-H524b) at 2 μg/mL (100 μL/well) can bind Human CD30 Protein, Llama IgG2b Fc Tag (Cat. No. TN8-H5250) with a linear range of 0.6-10 ng/mL (Routinely tested).

    Protocol
  • Bioactivity-BLI

     CD30 ligand BLI

    Loaded Biotinylated Human CD30, Avitag,His Tag (Cat. No. CD0-H82E6) on SA Biosensor, can bind Human CD30 Ligand Protein, His Tag (Cat. No. CDL-H524b) with an affinity constant of 132 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

    Protocol
  • Bioactivity-Flow Cytometry

     CD30 ligand FACS

    FACS analysis shows that Human CD30 Ligand Protein, His Tag (Cat. No. CDL-H524b) can bind to K562-CD30 cells surface CD30. The concentration of Human CD30 Ligand is 3 μg/mL (Routinely tested).

    Protocol
  •  CD30 ligand FACS

    FACS analysis shows that the binding of Human CD30 Ligand Protein, His Tag (Cat. No. CDL-H524b) to K562-CD30 cells surface CD30 was inhibited by increasing concentration of neutralizing anti-CD30 antibody. The concentration of Human CD30 Ligand used is 3 μg/mL. The IC50 is 0.2401 μg/mL (Routinely tested).

    Protocol

Customer Reviews
Writing Reviews

FAQ

  • product

    Can lyophilized proteins remain stable during room-temperature shipping or temporary room-temperature exposure?

    In general, lyophilized proteins remain stable during room-temperature shipping or temporary exposure to room-temperature conditions.


    Many ACROBiosystems recombinant proteins are supplied in lyophilized (freeze-dried) form. The lyophilization process effectively removes moisture from the product, helping reduce degradation-related reactions and improve protein stability during transportation and storage.


    To evaluate the stability of lyophilized proteins under normal temperature conditions, ACROBiosystems conducted a stability study on 11 representative lyophilized protein products at 37°C. The study demonstrated that these proteins maintained good quality stability after storage at 37°C for approximately 20 days. Based on these validation results, temporary room-temperature exposure during shipping or handling is generally not expected to have a significant impact on product quality or downstream application performance.


    To ensure optimal long-term stability, products should be stored according to the storage conditions specified in the product Certificate of Analysis (COA) upon receipt.


    Supporting Document


Background

CD30 ligand (CD30L) and CD30 are interacting cellsurface glycoproteins that are members of the tumour necrosis factor (TNF) and tumour necrosis factor receptor
(TNFR) superfamilies. In humans, CD30L is expressed at high levels on activated T cells. There is conflicting evidence with regard to cell surface expression of CD30L on primary human B cells. An initial report of constitutive CD30L expression on peripheral blood B cells33 has not been substantiated.

Recent Advances

 
Drug Development Progress
  • English Name:

    Tumor necrosis factor ligand superfamily member 8

  • Category:

  • Approved Drugs:

    0 Details

  • Drugs in Clinical Trials:

    0 Details

  • Highest Development Stage:

    Preclinical

Drug Candidate Licensing
More
  • Basic Product Information
  • Product Details
  • Customers Also Viewed
  • Performance Data
  • Customer Reviews
  • FAQ
  • Background